Articles

Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies

Yilun Wang,^{a,1} Jie Wei,^{b,c,1} Weiya Zhang,^{d,e} Michael Doherty,^{d,e} Yuqing Zhang,^{f,g} Haibin Xie,^a Wei Li,^a Ning Wang,^a Guanghua Lei,^{a,c,h}* and Chao Zeng ^{a,c,h}*

^aDepartment of Orthopaedics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China ^bHealth Management Center, Xiangya Hospital, Central South University, Changsha, China

^cHunan Key Laboratory of Joint Degeneration and Injury, Changsha, China

^dUniversity of Nottingham, Nottingham, UK

^ePain Centre Versus Arthritis UK, Nottingham, UK

^fDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA

^gThe Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, USA

^hNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

Summary

Background Emerging evidence suggests that dysbiosis in gut microbiota may contribute to the occurrence or development of several rheumatic diseases. Since gut microbiota dysbiosis is potentially modifiable, it has been postulated to be a promising preventive or therapeutic target for rheumatic diseases. However, the current understanding on the potential associations between gut microbiota and rheumatic diseases is still inadequate. Therefore, we aimed to synthesise the accumulating evidence for the relation of gut microbiota to rheumatic diseases.



eBioMedicine 2022;80: 104055 Published online 17 May 2022 https://doi.org/10.1016/j. ebiom.2022.104055

Methods The PubMed, Embase and Cochrane Library were searched from inception to March 11, 2022 to include observational studies evaluating the associations between gut microbiota and rheumatic diseases. Standardised mean difference (SMD) of α -diversity indices between rheumatic diseases and controls were estimated using random-effects model. β -diversity indices and relative abundance of gut microbes were summarised qualitatively.

Findings Of the included 92 studies (11,998 participants), 68 provided data for α -diversity. Taken together as a whole, decreases in α -diversity indices were consistently found in rheumatic diseases (observed species: SMD = -0.36, [95%CI = -0.63, -0.09]; Chao1: SMD = -0.57, [95%CI = -0.88, -0.26]; Shannon index: SMD = -0.33, [95%CI = -0.48, -0.17]; Simpson index: SMD = -0.32, [95%CI = -0.49, -0.14]). However, when specific rheumatic diseases were examined, decreases were only observed in rheumatoid arthritis (observed species: SMD = -0.51, [95%CI = -0.78, -0.24]; Shannon index: SMD = -0.31, [95%CI = -0.49, -0.13]; Simpson index: SMD = -0.31, [95%CI = -0.49, -0.13]; Simpson index: SMD = -0.31, [95%CI = -0.54, -0.08]), systemic lupus erythematosus (Chao1: SMD = -1.60, [95%CI = -2.54, -0.66]; Shannon index: SMD = -0.63, [95%CI = -1.08, -0.18]), gout (Simpson index: SMD = -0.64, [95%CI = -1.07, -0.22]) and fibromyalgia (Simpson index: SMD = -0.28, [95%CI = -0.44, -0.11]), whereas an increase was observed in systemic sclerosis (Shannon index: SMD = 1.25, [95%CI = -0.44, -0.11]), whereas an increase was observed in systemic sclerosis (Shannon index: SMD = 1.25, [95%CI = -0.9, 2.41]). Differences with statistical significance in β -diversity were consistently reported in ankylosing spondylitis and IgG4-related diseases. Although little evidence of disease specificity of gut microbes was found, shared alterations of the depletion of anti-inflammatory butyrate-producing microbe (i.e., *Faecalibacterium*) and the enrichment of pro-inflammatory microbe (i.e., *Streptococcus*) were observed in rheumatoid arthritis, Sjögren's syndrome and systemic lupus erythematosus.

Interpretation Gut microbiota dysbiosis was associated with rheumatic diseases, principally with potentially non-specific, shared alterations of microbes.

Funding National Natural Science Foundation of China (81930071, 81902265, 82072502 and U21A20352).

Copyright © 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

E-mail addresses: lei_guanghua@csu.edu.cn (G. Lei), zengchao@csu.edu.cn (C. Zeng).

¹ These authors contributed equally to this work.

^{*}Corresponding authors at: Department of Orthopaedics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China.

Keywords: Gut microbiota; Gut dysbiosis; Rheumatic diseases; Meta-analysis

Research in context

Evidence before this study

We searched PubMed, Embase and Cochrane Library databases for observational studies evaluating the association between gut microbiota and rheumatic diseases, from inception to March 11, 2022, with no language restrictions. We identified 92 observational studies with inconsistent results on the precise relationship between the human gut microbiota and specific rheumatic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, osteoarthritis and Sjögren's syndrome). Several systematic reviews on gut dysbiosis in specific rheumatic diseases have been published. However, these systematic reviews have focused on only one specific rheumatic disease, and thus are not always suitable to answer some research questions. For example, the identification of disease-specific gut microbes, which are consistently enriched or depleted in a rheumatic disease, would shed light on disease diagnostics and phenotyping, a pathway to intervention or therapy, or to address causality. In addition, the identification of non-specific and shared gut microbes across different rheumatic diseases is also important because this knowledge could help us understand potentially shared pathogenesis of multiple rheumatic conditions.

Added value of this study

Through a systematic review and meta-analysis based on 92 observational studies with 11,998 participants spanning 14 rheumatic diseases, we provided comprehensive evidence that gut microbiota dysbiosis were associated with a shared alteration with a depletion of anti-inflammatory butyrate-producing microbe (i.e., *Faecalibacterium*) and an enrichment of pro-inflammatory microbe (i.e., *Streptococcus*) in rheumatic diseases in general. Meanwhile, evidence of distinct disease-specific alterations in gut microbes was sparse.

Implications of all the available evidence

Studies should be interpreted with caution, as many identified microbial associations may be indicative of a shared alteration to multiple rheumatic diseases rather than a disease-specific biological difference. These microbes and their metabolites could also be used as general targets for innovative preventive or therapeutic tools for different rheumatic diseases. In addition, little evidence of distinct disease-specific alterations in gut microbes was evident. This suggests that gut microbes serving as diagnostics for specific rheumatic diseases warrants further studies.

Introduction

The human gut is colonised by a complex microbial ecosystem, collectively called the gut microbiota, which plays a pivotal role in key biological processes such as metabolic interactions and host immune responses.¹⁻⁴ The gut microbiota has an association not only with the well-being of human but also with a range of disease conditions, such as obesity, growth disorders, metabolic diseases, and mental illness.^{5–9} The emerging evidence in the past decades suggests that dysbiosis in gut microbiota and its impact on the balance between pro- and anti-inflammatory immune responses¹⁰ may contribute to the occurrence or development of several rheumatic diseases, such as rheumatoid arthritis,¹¹⁻¹³ ankylosing spondylitis,^{14,15} systemic lupus erythematosus,^{16,17} systemic sclerosis,^{18,19} Sjogren's syndrome,^{20,21} and osteoarthritis.^{22,23} Since gut microbiota dysbiosis is potentially modifiable, it has been postulated to be a promising preventive or therapeutic target for rheumatic diseases.^{24,25}

However, the current understanding on the potential associations between gut microbiota and rheumatic diseases are far from adequacy.^{26,27} For example, there has been a common assumption that high α -diversity (e.g., taxonomic richness and evenness) is desirable for the gut microbial ecosystem²⁸; however, results from individual studies with various sample sizes are inconsistent.²⁹⁻³² In addition, the identification of diseasespecific gut microbes, which are consistently depleted or enriched in disease conditions across different populations with various characteristics, would shed light on disease diagnostics and phenotyping, a pathway to intervention or therapy, or to address causality.33 Furthermore, the identification of non-specific and shared gut microbes across different rheumatic diseases is also important because this knowledge could help us understand potentially shared pathogenesis of multiple rheumatic conditions.³⁴ However, these research questions remain unsolved, and individual studies are not always suitable to answer them.

Systematic review and meta-analysis is a powerful approach to synthesise the existing knowledge for the purpose of identifying consistencies across multiple studies, but to our best knowledge, no such research work has been performed yet on gut microbiota alterations across a spectrum of rheumatic diseases. Therefore, our study aimed to synthesise the accumulating evidence on the associations between gut microbiota and multiple rheumatic diseases.

Methods

Protocol

The protocol of study was preregistered with PROS-PERO (CRD42021282397). The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline³⁵ was followed.

Search details

Two independent investigators (Wei Li and Haibin Xie) from the research team were responsible for systematic literature search across PubMed, Embase and Cochrane Library databases from inception to March II, 2022 (see **Appendix I** for the full electronic search strategy). No restriction was applied, and non-English written articles were translated. For all the finally included articles, their references and related reviews were manually reviewed.

Selection criteria

The same two investigators (Wei Li and Haibin Xie) implemented study selection on an independent basis by firstly screening the titles and abstracts, followed by reviewing the full texts of eligible articles. Disagreements, if any, were resolved by consulting a third investigator (Yilun Wang). Specifically, the inclusion criteria were: (I) applied an observational design (e.g., case-control study, cross-sectional study, and cohort study); (2) performed gut microbiota analysis with available data on diversity or abundance measures; and (3) included participants with a rheumatic disease.

Data extraction

A pre-designed template was used to extract desired information, which was then cross-checked by four investigators (Yilun Wang, Wei Li, Haibin Xie and Ning Wang). The primary outcomes of interest were community-level measures of gut microbiota composition (i.e., α -diversity and β -diversity) and phylum-, family- and genus-level taxonomic findings (i.e., relative abundance). The α -diversity, as a summary of microbial community in individual samples, can be compared among multiple groups to assess the richness (i.e., number of taxa) and evenness (i.e., how well each taxon is represented) in the sample.³⁶ The β -diversity can be used to measure the inter-sample diversity that assesses the phylogenetic structure of communities in comparison with other samples analysed. In addition, other information including publication details, participant demographics and methodology was also extracted.

Quality assessment

The methodological quality of included studies was examined by two reviewers (Wei Li and Haibin Xie) independently based on the Newcastle–Ottawa Scale (NOS). Any disagreement in quality scoring would be resolved by mutual discussion as far as possible; if failed, the first author (Yilun Wang) would make the final verdict. The NOS is a quality assessment approach for observational studies based on three criteria: selection, comparability, and outcome. Under recommendation by the Cochrane Collaboration, it has been widely adopted to assess the quality and bias of systematic reviews and meta-analyses.³⁷ A total NOS score of \leq 5 was considered low quality, 6 or 7 was considered moderate quality, and 8 or 9 was considered high quality.³⁸

Statistics

Quantitative synthesis. We performed a meta-analysis on the differences in α -diversity (e.g., observed species, Chao1, abundance coverage estimator, incidence coverage estimator, Pielou, Shannon index, Simpson index, inverse Simpson index, and faith phylogenetic diversity) between patients with rheumatic diseases and individuals without rheumatic diseases (i.e., controls) in terms of the indices with data available in at least 10 studies.³⁶ The pooled standardised mean difference (SMD) and its 95% confidence interval (CI) were computed for each index through inverse-variance random-effects metaanalysis. The effect size was categorised as trivial (SMD \leq 0.2), small (0.2 < SMD < 0.5), moderate $(0.5 \le SMD < 0.8)$, or large $(SMD \ge 0.8)$.³⁶ Medians and inter-quartile ranges were converted to means and standard deviations (SD).³⁹ Where necessary, numerical data was extracted from graphs using WebPlotDigitizer V.4.42. The inter-study heterogeneity was quantified by the DerSimonian-Laird estimator, and was interpreted based on the I^2 statistic ($I^2 > 50\%$ was considered heterogeneous).4° Publication bias was examined by funnel plots and Egger's test.

As part of our meta-analysis, three subgroup analyses were performed, which were stratified by the specific type of rheumatic disease, the regional distribution of study populations (i.e., Eastern countries versus Western countries), and the administration of antirheumatic medication (i.e., on treatment versus treatment naÿve), respectively. While grouping the participants from Eastern and Western countries, typical lifestyle and diet habit were considered to control for geographical differences in genetics and diet. More specifically, Eastern countries were defined as countries or regions in East and South Asia, whereas western countries referred to those in Europe, North America, Oceania and Middle East. A study with \geq 80% of the patients receiving antirheumatic medications (e.g., nonsteroidal anti-inflammatory drugs and disease-modifying anti-inflammatory drugs) was considered a study with patients on treatment.³⁶ Further, two sensitivity analyses were conducted to evaluate the robustness of findings by removing low-quality studies (NOS \leq 5) and those with no matching of any variable, since such studies were susceptible to confounding bias (e.g., age, sex and body mass index).

All analyses were conducted in Review Manager V.5.2 (RevMan V.5.2, The Cochrane Collaboration, Oxford, UK) and STATA V.11.0 (StataCorp LP). *P* values less than 0.05 were considered statistically significant.

Qualitative synthesis. Differences in β -diversity between patients with rheumatic diseases and controls were summarised in a qualitative manner. A consistently different β -diversity was defined as that all included studies for a specific disease reported significant differences in β -diversity between patients and controls. To confirm disease-specific and shared alterations, we firstly summarised within disease findings for each microbe reported by at least two studies.³⁶ Then, we categorised those microbes using the following rules³⁶: (1) the microbes were labelled as increased, decreased, or "not consistent" in patients with rheumatic disease versus the control group; (2) a "not consistent" finding was defined as any finding with < 75% agreement among studies reporting this microbe; (3) a consistent finding among three or more studies (from at least two research groups) was considered potentially associated with the disease, whereas a consistent finding between only two studies was deemed worth future verification; (4) a microbe was regarded as a candidate for disease-specific alteration if it was altered (in a consistent direction) in one disease only; (5) a shift replicated across at least three rheumatic diseases was considered a shared alteration.

Role of the funding source

The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Ethics

Since no private or confidential patient data will be contained in the reporting, approval from an ethics committee is not required.

Results

Search results

A total of 2,741 articles were preliminarily retrieved from the database search, and 92 studies across 14 rheumatic diseases were included (**Appendix 2**). The most researched disease was rheumatoid arthritis, followed by systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, osteoarthritis and Sjögren's syndrome. Regarding individual diagnoses, the total number of included participants varied from 77 (psoriatic arthritis) to 2,184 (rheumatoid arthritis), the mean age ranged from 2.6 (Kawasaki disease) to 63.7 (osteoarthritis) years, and the percentage of females ranged from 4.1% (gout) to 95% (fibromyalgia) (Table 1).

Characteristics of included studies

Characteristics of included studies are presented in Appendix 3. Slightly over half of the studies (53 [57.6%]) were carried out in Eastern countries, 38 (41.3%) in Western countries, and only I (I.I%) in Africa. Medication usage varied substantially, with 25 studies (27.2%) performed in medication-free or drug-naive groups, 9 studies (9.8%) in groups on treatment, and the remainder not controlling for this, resulting in anywhere between 13.0% and 89.7% of patients receiving medication. The methodology of stool processing (Appendix 4) and composition analysis (Appendix 5) also varied remarkably, with 16S ribosomal RNA (rRNA) sequencing being most commonly adopted (75 studies [81.5%]), followed by shotgun metagenomics (13 studies [14.1%]), quantitative polymerase chain reaction or real-time quantitative polymerase chain reaction (3 studies [3.3%]), and GA-map Dysbiosis test (I study [I.I%]). Matching-variables between patients and controls in each included study are listed in Appendix 3. A total of 21 studies did not match any variable. The NOS of the included studies ranged from 2-8 (Appendix 6). According to the total NOS score, 31 of the included studies were rated as low quality, 54 were rated as moderate quality, and 7 were rated as high quality.

α -diversity

Sixty-eight studies provided data for α -diversity, which was then assessed by 7 indices, namely estimates of richness (observed species, Chaoi, abundance coverage estimator), evenness (Pielou), richness/evenness (Shannon, Simpson), and biodiversity (Faith phylogenetic diversity). Among them, 4 indices with sufficient studies ($n \ge 10$) (i.e., observed species, Chaoi, Shannon index and Simpson index) were included in the meta-analysis. No evidence of publication bias was found in any analysis (**Appendix** 7).

As for the richness, 26 studies reported data on observed species in patients with rheumatic diseases (n = 1,311) versus controls (n = 994). Taken together as a whole, the pooled estimate indicated a significant decrease of gut microbiome richness in the patients with rheumatic diseases versus controls, though showing a small effect size (SMD = -0.36, [95%CI = -0.63, -0.09], P = 0.01; inverse-variance, random-effects) and high heterogeneity ($I^2 = 88\%$). When specific diseases were examined, a significant decrease of gut microbiome richness was observed only in rheumatoid arthritis (SMD = -0.51, [95%CI = -0.78, -0.24], P < 0.001, $I^2 = 65\%$; inverse-variance, random-effects) (Figure 1a). Thirty studies reported data on Chao1 in patients with

Disorder	Included studies	Number of participants	Mean age	Female ratio
Rheumatoid arthritis	21	2,184	45.3	58.6
Systemic lupus erythematosus	15	2,040	40.4	70.8
Ankylosing spondylitis	13	1,214	41.4	34.3
Systemic sclerosis	9	765	54.8	77.5
Osteoarthritis	7	1,887	63.7	62.3
Sjögren's syndrome	6	1,176	51.9	58.4
Gout	5	402	43.8	4.1
Juvenile idiopathic arthritis	5	490	9.0	55.0
Behcet's disease	4	217	42.4	69.8
Fibromyalgia	4	2,141	60.2	95.0
lgG4-related diseases	2	321	55.5	56.5
Kawasaki disease	2	154	2.6	47.9
Psoriatic arthritis	2	77	44.1	64.9
Microscopic polyangiitis	1	105	60.0	NA

NA, not available.

rheumatic diseases (n = 1,495) versus controls (n = 3,244). The pooled estimate for combined rheumatic diseases indicated a significant decrease versus controls with a moderate effect size (SMD = -0.57, [95%CI = -0.88, -0.26], P < 0.001, I² = 93%; inversevariance, random-effects), but individually, a significant decrease was found only in systemic lupus erythematosus (SMD = -1.60, [95%CI = -2.54, -0.66], P < 0.001, I² = 94%; inversevariance, random-effects) (Figure 1b).

As for the richness/evenness, 58 studies reported the Shannon index in patients with rheumatic diseases (n = 2,893) versus controls (n = 7,444). A significant decrease in the combined rheumatic diseases with a small effect size (SMD = -0.33, [95%CI = -0.48, -0.17], P < 0.001; inverse-variance, random-effects) but high heterogeneity ($I^2 = 87\%$) was found by pooling the data during meta-analysis. However, when specific diseases were examined, there was a significant decrease in rheumatoid arthritis (SMD = -0.3I, [95%CI = -0.49, -0.13], P < 0.001, $I^2 = 63\%$; inversevariance, random-effects) and systemic lupus erythematosus (SMD = -0.63, [95%CI = -1.08, -0.18], P = 0.007, $I^2 = 82\%$; inverse-variance, random-effects); and there was a significant increase in systemic sclerosis (SMD = 1.25, [95%CI = 0.09, 2.41], P = 0.03, $I^2 = 96\%$; inverse-variance, random-effects) (Figure 2a). Twenty-seven studies reported the Simpson index (n = 1,460 patients; n = 2,903 controls), and the pooled effect size indicated a significant decrease in the combined rheumatic diseases with a small effect size (SMD = -0.32, [95%CI = -0.49, -0.14], P < 0.001, $I^2 = 79\%$; inverse-variance, random-effects). When the associations between gut microbiome richness/evenness and specific rheumatic diseases were assessed, a significant decrease in gut microbiome richness/evenness was observed only in rheumatoid arthritis $(SMD = -0.3I, [95\%CI = -0.54, -0.08], P = 0.007, I^2 = 48\%$; inverse-variance, random-effects), gout $(SMD = -0.64, [95\%CI = -1.07, -0.22], P = 0.003, I^2 = 69\%$; inverse-variance, random-effects), and fibro-myalgia $(SMD = -0.28, [95\%CI = -0.44, -0.11], P = 0.001, I^2 = 0\%$; inverse-variance, random-effects) (Figure 2b).

We further conducted subgroup analyses according to the regional distribution of the included participants for the purpose of understanding the sources of inter-study heterogeneity. Most of the α -diversity indices showed a decrease in patients from Eastern countries only rather than those from Western countries. Substantial heterogeneity, however, was still observed (I² ranged from 62 to 95%) (Appendix 8). Then, we also compared results from medication-free or drug-naÿve studies with those from studies with patients on treatment ($\geq 80\%$ of the patients receiving medications) (Appendix 9). Decreases in α -diversity indices were mainly seen in studies where patients did not receive any treatment. Heterogeneity of the Simpson index was substantially reduced, and the SMD did not vary significantly in studies with patients on treatment (SMD = -0.61, [95%CI = -0.84, -0.37], P < 0.001, $I^2 = 0\%$; inverse-variance, random-effects). In addition, sensitivity analyses were performed by removing low-quality studies (Appendix 10) and those with no matching of any variable (Appendix II), and all α -diversity indices were still significantly decreased in patients with rheumatic diseases versus controls. However, substantial heterogeneity still existed (I^2 ranged from 76 to 94%).

β-diversity

The comparison of β -diversity between patients with rheumatic diseases and controls was conducted in 64 studies (Figure 3). More than half of the studies in 7 rheumatic diseases (i.e., rheumatoid arthritis, systemic

a Observed species

b Chao1

	_								
Phudu na Pulanaun	Exp	erimental	Tetal	Maan	control	Tatal	Mainht	Std. Mean Difference	Std. Mean Difference
1 1 1 Rheumatoid arthritis	mean	30	Total	mean	30	Total	weight	iv, Kandom, 55% Ci	iv, Randolii, 95% Ci
Aloizar-Podriguez-2019	102.0	48.00	83	108 11	55.01	50	3.8%		-0.101-0.45_0.251
Breban-2017	442.57	85.76	49	585.48	105.9	18	3.4%		-1 54 [-2 15 -0 94]
Chiang-2019	169.91	103.34	128	212.54	63.95	20	3.6%		-0.43 [-0.90, 0.05]
Jeong-2019	154.37	44.18	29	183.92	85.89	25	3.5%		-0.44 [-0.98, 0.11]
Jeong-2021 a	176.1	98.15	16	254.09	127.29	16	3.1%		-0.67 [-1.38, 0.05]
Jeong-2021 b	165.41	60.96	24	254.09	127.29	16	3.2%		-0.93 [-1.60, -0.27]
Jeong-2021 c	181.13	60.39	53	254.09	127.29	16	3.4%		-0.90 [-1.48, -0.32]
Kim-2021	160.49	58.25	32	217.24	108.55	15	3.3%		-0.72 [-1.35, -0.09]
Mei-2021	99.59	15.98	22	96.58	9.82	22	3.4%		0.22 [-0.37, 0.82]
Picchianti-Diamanti-2018	401.35	71.91	11	388.49	62.43	10	2.9%		0.18 [+0.68, 1.04]
Wang-2022*	13.74	3.94	108	15.33	3.76	99	3.9%		-0.41 [-0.69, -0.14]
Subtotal (95% CI)			555			307	37.4%	+	-0.51 [-0.78, -0.24]
Test for overall effect: P = 0	.0002; Het	terogeneity	! ² = 6	5%, P = 0.0	001				
1.1.2 Ankylosing spondyli	tis								
Costello-2015	664.94	79.52	9	421.65	131.77	9	2.3%		2.13 [0.92, 3.34]
Li-2019	194.72	54.77	41	179.7	66.28	30	3.7%		0.25 [+0.22, 0.72]
Sun-2021	397.29	59.62	. 9	399.46	43.36	9	2.8%		-0.04 [-0.96, 0.88]
Y In-2020	71.02	11.32	97	68.61	12.04	93	4.0%		0.21 [-0.08, 0.49]
Zhang-2019 Subtatal (05%, Ch	1/6.43	/1.64	103	188.2	63.24	105	4.0%	1	-0.17 [-0.45, 0.10]
ountotal (95% CI)	05.11.4		259	D - 0.07		246	16.8%	T	0.24 [-0.17, 0.06]
Test for overall effect: P = 0	.25; Hetero	ogeneity: P	= 74%	, P = 0.004					
1.1.3 Systemic lunus envil	amatosus								
Chen-2021***	105.14		117	101.02	14.01	115	3.0%	1	0.15 L0.11 0.401
Gue 2020	270.80	56 32	17	210	32.09	20	3.5%		1 51 [0 77 2 26]
Ho 2020	202.02	10.15	24	224.27	6.00	10	2.6%		2 20 [2 29 4 44]
16-2020	265.28	65.15	40	317.50	74.85	22	3.5%		-0.75[-1.29]-0.21]
Subtotal (95% Cl)	200.20	00.10	195	017.00	74.00	167	13.1%	-	-0.32 [-1.43, 0.78]
Test for overall effect: P = 0	.57: Hetero	paeneity; l ²	= 94%	P < 0.000	01			-	
		• ,							
1.1.4 Systemic sclerosis									
Levin-2021 a	107.34	9.4	13	119.5	9.86	20	3.0%		-1.22 [-1.99, -0.46]
Levin-2021 b	149.31	11.35	13	119.5	9.86	20	2.6%		2.78 [1.78, 3.78]
Patrone-2017 a	687.94	150.55	9	596.78	125.22	9	2.7%		0.63 [-0.33, 1.58]
Patrone-2017 b	215.01	56.28	9	596.78	125.22	9	1.6%		-3.75 [-5.41, -2.08]
Subtotal (95% CI)			44			58	9.8%		-0.33 [-2.62, 1.97]
Test for overall effect: P = 0	.78; Heter	ogeneity: l ^a	= 95%	6, P < 0.00	001				
1.1.5 Gout									
Méndez-Salazar-2021	152.71	21.4	25	169.07	41.01	53	3.6%		-0.45 [-0.93, 0.03]
Shao-2017	2,172.16	603.33	26	5,417.58	948.1	26	2.6%		-4.02 [-4.99, -3.05]
Subtotal (95% CI)			51			79	6.2%		-2.21 [-5.71, 1.29]
Test for overall effect: P = 0	.22; Hetero	ogeneity: I ²	= 98%	, P < 0.000	01				
1.1.6 Behcet's disease									
Shimizu-2016	3,335.18	2,360.16	12	3,994.46	1,872.33	12	3.0%		-0.30 [-1.10, 0.51]
Subtotal (95% CI)			12			12	3.0%	T	-0.30 [-1.10, 0.51]
Test for overall effect: P = 0	.47; Hetero	ogeneity: N	ot app	licable					
1 1 7 Eibromuolaio									
Clas Cassis 2010	70.0	10.00	105	00.0	20.00	<i>e</i> •	2.05		0.221.0.88.0.001
Subtotal (95%, CI)	73.8	18.89	105	80.3	20.98	04 54	3.8%		-0.33 [-0.00, 0.00]
Tool for overall offer 1 D = 0	OF: Hot	agagaity **	105	liaoblo		54	3.076	4	-0.55 [-0.00, 0.00]
rescior overall effect: P = 0	.05, neten	ogeneity: N	or app	Incapid					
118 Juvenile idionethic a	rthritie								
Accentral-2017	906.04	304.97	32	934 77	172.72	14	3.394		-0.101-0.73_0.521
Subtotal (95% CI)	500.04	304.87	33	004.11	112.13	14	3.3%		-0.10[0.73,0.02]
Test for overall effect: P = 0	75: Heten	ogeneity: N	lot ann	licable		.4	01070	T	Found even1
reactor overall ellett: P = 0		oganeny: N	or abb	nudure					
1.1.9 Osteoarthritis									
Chen-2021*	50.37	3.82	57	52.31	6.1	57	3.8%		-0.38 (-0.75 -0.01)
Subtotal (95% CI)	00.07	0.02	57	02.01	0.1	57	3.8%		-0.38 [-0.750.01]
Test for overall effect: P = 0	05: Heteo	openeity: N	ot app	licable		- /	/*	*	
. Las for overall enoble P = 0		- <i>a</i> shony . In	- copp						
T-1-1 (059) (01)			4244			004	400.0%		0.2610.62 0.001
rotal (95% CI)			1311		004	994	100.0%		-0.30 [-0.63, -0.04]
rest for overall effect: P = 0	curu; Hete	rogeneity: F	885	s, P < 0.00	001			-4 -2 0 2 4	
								Decreased Increased	

	Exp	erimental		0	Control			Std. Mean Difference	Std. Mean Difference
itudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% C
.2.1 Juvenile idiopati	nic arthritis							l l	
kggarwal-2017	1,462.53	464.61	33	1,405.54	289.37	14	2.7%		0.13 [-0.49, 0.76]
)ijkhuizen-2019 a	208.97	34.81	5	232.05	189.01	8	2.2%		-0.14 [-1.26, 0.98]
Njkhuizen-2019 b	140.38	45.08	17	260.9	140.35	41	2.7%		-0.98 [-1.58, -0.39]
) jkhuizen-2019 c	255.21	96.84	16	182.29	68.56	20	2.6%		0.87 [0.18, 1.56]
Nikhuizen-2019 d	231.77	157.19	61	278.65	159.5	38	2.9%	**)	-0.29 [-0.70, 0.11]
an-2020	362.95	135.79	39	447.03	113.43	42	2.9%	***	-0.67 [-1.12, -0.22]
0man-2020	969.72	227	75	878.86	182.97	24	2.8%	***	0.411-0.05.0.881
iubtotal (95% CI)			246			187	18.9%		-0.11 [-0.57, 0.35]
'est for overall effect: F	e = 0.64; Heterog	peneity: I ² = 795	6, P < 0	.0001					
2.2 Systemic lupus	rythematosus								
uzzouz-2019	954.72	50.94	61	1,156.6	84.91	17	2.6%		-3.35 [-4.11, -2.59]
fellocchi-2019	1,759.53	585.95	27	1,832.12	300.43	27	2.8%	. 1	-0.15 [-0.69, 0.38]
le-2020	237.5	8.33	21	256.94	6.33	10	2.3%		-2.44 [-3.43, -1.44]
i-2019*	317.95	80.44	40	360.51	82.91	22	2.8%		-0.52 [-1.05, 0.01]
iu-2021*	1.91	0.35	35	2.58	0.11	35	2.7%		-2.55 [-3.19, -1.91]
Aeulen-2018	113.69	11.66	30	124.92	13.32	965	2.9%		-0.85 [-1.21, -0.48]
iubtotal (95% CI)			214			1076	16.1%	•	-1.60 [-2.54, -0.66]
est for overall effect: F	P = 0.0008; Heter	rogeneity: I* = 9	4%, P	< 0.00001					
.2.3 Sjögren syndron	10			4 000 00	000.000		0.00		0.001.0.40.5.55
enoconi-2019	1,867.23	566.96	23	1,832.39	296.27	- 27	2.8%		0.08 [-0.48, 0.63]
ano-Ortiz-2020	20.05	7.28	19	28.05	3.11	19	2.6%		-1.40 [-2.12, -0.68]
Aeulen-2018	115.93	11.73	39	124.92	13.32	965	2.9%		-0.68 [-1.00, -0.36]
Aoon-2020	571.43	363.45	10	471.56	144.76	12	2.5%		0.36 [-0.49, 1.21]
Vang-2020 a	209.66	20.99	9	186.51	17.26	10	2.3%		1.16 [0.17, 2.15]
Vang-2020 b	164.43	29.28	9	186.51	17.26	10	2.4%		-0.89 [+1.85, 0.06]
Subtotal (95% CI)			109			1043	15.5%	*	-0.27 [-0.89, 0.35]
'est for overall effect: F	= 0.39; Heterog	eneity: I* = 81%	, P < 0	0001					
.2.4 Rheumatoid arth	ritis								
then-2021**	265.18	4.71	29	253.4	5.5	30	2.7%		2.27 [1.60, 2.93]
orbes-2018	430.81	157.76	21	484.33	131.01	23	2.7%		-0.36 [-0.96, 0.23]
i-2021	234.55	112.22	205	274.95	95.04	199	3.0%		-0.39 [-0.58, -0.19]
Aena-Vázquez-2020	1,132.72	271.6	40	1,104.94	250	40	2.9%		0.11 [-0.33, 0.54]
Vang-2022*	25.83	14.4	108	31.67	16.3	99	3.0%	~	-0.38 [-0.65, -0.10]
lubtotal (95% CI)			403			391	14.2%	+	0.19 [-0.44, 0.83]
est for overall effect: F	= 0.55; Heterog	eneity: I ² = 93%	, P < 0	.00001					
.2.5 Ankylosing spor	dylitis								
iu-2020	323.6	17.88	10	335.09	34.21	12	2.5%		-0.39 [-1.24. 0.46]
hana.2019	225.12	73.26	102	235.0	60.91	105	3.0%	-	0.161-0.43.0.111
2020 Theory 2020	101.44	9.07	100	104.09	7.46	10	1.000		2 22 11 95 4 621
iubtotal (95% CI)			124			127	7.3%	-	0.74 [-0.78, 2.26]
est for overall effect: P	= 0.34; Heterog	eneity: I ² = 91%	, P < 0	.0001					
.2.6 Systemic scleros	sis								
vndréasson-2022	391.6	101.05	106	360.22	96.33	85	3.0%		0.32 [0.03, 0.60]
Patrone-2017 a	2.608.923885	702.4990234	9	2.139.107612	723.1607594	9	2.4%		0.63 (-0.32, 1.58)
Patrone-2017 b	356.9553806	110.1959252	9	2.139.107612	723.1607594	9	1.8%		-3.28 I-4.811.761
Subtotal (95% CI)			124			103	7.1%	-	-0.61 [-2.23, 1.02]
est for overall effect: F	= 0.46; Heterog	eneity: I² = 91%	P < 0	.0001					
.2.7 Behcet's disease									
Shimizu-2016	17,874.64	4,657.51	12	15,377.82	4,192.97	12	2.5%		0.54 [-0.27, 1.36]
ecer-2020	40	0.59	7	45.38	4.59	16	2.3%		-1.33 [-2.32, -0.35]
Subtotal (95% CI)		0000 H = 0000	19	004		28	4.8%	-	-0.37 [-2.21, 1.46]
es or overall effect h	- 0.09; meterog	orreity: 1* = 88%	. e = 0	.004					
.2.8 Gout	480.00	01.07	20	400	10		2.05		0444000
New 2017	103,49	21.27	25	169.44	40.44	03	2.8%		9.9714.09 0.004
	10,100.43	2,019.89	28	34,705.88	9,000.82	26	2.0%		-3.37 [-4.23, -2.50]
hubbotal (95%, CP		eneity 12 = 07%	- 01 P < 0	00001		19	0.3%		-1.00 [-4.70, 0.98]
iubtotal (95% CI) est for overall effect: F	= 0.20: Heteroo								
Subtotal (95% CI) Set for overall effect: P	= 0.20; Heterog	onong.11 - 01 /a							
subtotal (95% CI) est for overall effect: F .2.9 Microscopic poly 0+2021 a	anglitis	98.00	35	207.5	52.04	34	2.8%		J1281J176 0 444
iubtotal (95% CI) est for overall effect: F .2.9 Microscopic poly /u-2021 a /u-2021 b	= 0.20; Heterog vangiitis 244.69 288.64	98.68	35 38	267.5	52.96	34	2.8%		-0.28 [-0.76, 0.19]
subtotal (95% CI) est for overall effect: F .2.9 Microscopic poly 'u-2021 a Jultotal (95% CI)	= 0.20; Heterog vangiitis 244.69 286.64	98.68 61.05	35 36 74	267.5 267.5	52.96 52.96	34 34 62	2.8% 2.8% 5.7 ^µ		-0.28 [-0.76, 0.19] 0.33 [-0.14, 0.80] 0.02 [-0.58, 0.623
subtotal (95% CI) est for overall effect: F /u-2021 a /u-2021 b subtotal (95% CI) est for overall effect: F	angiitis 244.69 286.64	98.68 61.05 eneity: P = 695	35 36 71 2 P = 0	267.5 267.5	52.96 52.96	34 34 68	2.8% 2.8% 5.7%	•	-0.28 [-0.76, 0.19] 0.33 [-0.14, 0.80] 0.02 [-0.58, 0.63]
subtotal (95% CI) est for overall effect: F .2.9 Microscopic poly 'u-2021 a 'u-2021 b subtotal (95% CI) est for overall effect: F 2.10 Koverant f	* = 0.20; Heterog vanglitis 244.69 286.64 * = 0.94; Heterog	98.68 61.05 jeneity: P = 695	35 36 71 5, P = 0	267.5 267.5	52.96 52.96	34 34 68	2.8% 2.8% 5.7%	*	-0.28 [-0.76, 0.19] 0.33 [-0.14, 0.80] 0.02 [-0.58, 0.63]
ubbotal (95% CI) est for overall effect: F .2.9 Microscopic pol; 'u-2021 a 'u-2021 b iubtotal (95% CI) 'est for overall effect: F .2.10 Kawasaki disea iliona 2020	* = 0.20; Heterog vangiitis 244.69 288.64 * = 0.94; Heterog se	98.68 61.05 reneity: P = 695	35 36 71 5 P = 0	267.5 267.5 .07	52.96 52.96	34 34 68	2.8% 2.8% 5.7%		-0.28 [-0.76, 0.19] 0.33 [-0.14, 0.80] 0.02 [-0.58, 0.63]
Subbolal (95%, CI) est for overall effect: F (-2.9 Microscopic poly (-2.021 a (-2.021 b Subbolal (95%, CI) est for overall effect: F (-2.10 Kawasaki disea (New-2020) (* = 0.20; Heterog vangiitis 244.69 286.64 * = 0.94; Heterog se 215.85	98.68 61.05 eneity: P = 695 75.07	35 36 71 5, P = 0 48	267.5 267.5 .07 725.76	52.96 52.96 60.67	34 34 68 46	2.8% 2.8% 5.7%		-0.28 [-0.76, 0.19] 0.33 [-0.14, 0.80] 0.02 [-0.58, 0.63] -7.39 [-8.55, -6.24]
Autobal (95%, CI) est for overall effect: F 2.9 Microscopic poly (u-2021 b liabtotal (95% CI) est for overall effect: F 2.10 Kawasaki disea ihen-2020 subbala (95% CI) est for overall effect: F est for overall effect: F	 = 0.20; Heterog 244.89 286.64 = 0.94; Heterog se 215.85 < 0.00001; Heterog 	98.68 61.05 eneity: P = 69% 75.07	35 38 71 5, P = 0 48 48 800/ica	267.5 267.5 .07 725.76 ble	52.96 52.96 60.67	34 34 68 46 46	2.8% 2.8% 5.7% 2.1% 2.1%	*	-7.39 [-8.55, -6.24] -7.39 [-8.55, -6.24]
Autobal (95% CI) Test for overall effect: F 2.9 Microscopic poly (u-2021 a (u-2021 a	* = 0.20; Heterog vangilitis 244.69 286.64 * = 0.94; Heterog se 215.85 * < 0.00001; Hete	98.68 61.05 reneity: P = 699 75.07 rogeneity: Not	35 38 71 3, P = 0 48 48 8pplica	267.5 267.5 .07 725.76 ble	52.96 52.96 60.67	34 34 68 46 46	2.8% 2.8% 5.7% 2.1% 2.1%	*	-7.39 [-8.55, -6.24] -7.39 [-8.55, -6.24]
Autotail (95%, CI) eest for overall effect: F 2.9 Microscopic poly (~2021 a (~2021 b lubtotail (95% CI) est for overall effect: F 2.10 Kawasaki disea ihen-2020 subtotail (95% CI) est for overall effect: F 2.11 Osteoarthritis Vang-2021	 = 0.20; Heterog z44.69 286.64 = 0.94; Heterog se 215.85 < 0.00001; Hete 779.79 	98.68 61.05 eneity: P = 68% 75.07 rrogeneity: Not. 296.82	35 36 71 5, P = 0 48 48 8pplica 86	267.5 267.5 .07 725.76 ble 1,143.29	52.96 52.96 60.67 415.5	34 34 68 46 46 96	2.8% 2.8% 5.7% 2.1% 2.1% 3.0%		-0.28 [-0.76, 0.19] 0.33 [-0.14, 0.80] 0.02 [-0.58, 0.63] -7.39 [-8.55, -6.24] -7.39 [-8.55, -6.24] -0.99 [-1.30, -0.68]
Labbohil (95% CI) est for overall effect: F 2.9 Microscopic poly 'u-2021 b Microscopic poly 'u-2021 b Microscopic poly 'u-2021 b Microscopic (95% CI) 'est for overall effect: F est for overall effect: F est for overall effect: F 2.11 Osteoarthritis Manp2021 Labbohal (95% CI)	 = 0.20; Heterog	98.68 61.05 eneity: P = 699 75.07 rogeneity: Not	35 36 71 5, P = 0 48 48 8pplica 86 86	267.5 267.5 .07 725.76 ble 1,143.29	52.96 52.96 60.67 415.5	34 34 68 46 46 96 96	2.8% 2.8% 5.7% 2.1% 2.1% 3.0% 3.0%	 +	-0.28 [-0.76, 0.19] 0.33 [-0.44, 0.80] 0.02 [-0.58, 0.63] -7.39 [-8.55, -6.24] -7.39 [-8.55, -6.24] -0.99 [-1.30, -0.68] -0.99 [-1.30, -0.68]
ubitotal (95% CI) es for overall effect: F. 2.9 Microscopic poly u-2021 a U-2021 b U-2021 b U-2021 b U-2021 b U-2021 b U-2021 b U-2021 b U-2021 b U-2021 b U-2021 b U-2020 U-2021 b U-2020 U-2020 U-2020 U-2020 U-2020 U-20	 = 0.20; Heterog yangilitis 244.69 286.64 = 0.94; Heterog se 215.85 < 0.00001; Heterog 779.79 < 0.00001; Heterog 	98.68 61.05 eneity: P = 695 75.07 rogeneity: Not 296.82 arogeneity: Not	35 36 71 5, P = 0 48 48 80 80 86 86 86 86	267.5 267.5 .07 725.76 ble 1,143.29 ble	52.96 52.96 60.67 415.5	34 34 68 46 46 96 96	2.8% 2.8% 5.7% 2.1% 2.1% 3.0% 3.0%	······································	-0.28 [-0.76, 0.79] 0.33 [-0.14, 0.80] 0.02 [-0.58, 0.63] -7.39 [-8.55, -6.24] -7.39 [-8.55, -6.24] -0.99 [-1.30, -0.68] -0.99 [-1.30, -0.68]
Liabitati (195% CI) iest for overal effect; 7 2.9 Microscopic poly (-2021 & Constantial (195% CI) iest for overal effect; Fi bishotati (195% CI) iest for overal effect; Fi bishotati (195% CI) iest for overal effect; Fi 2.11 Otateoarthritis Vang-2021 bishotati (195% CI) iest for overail effect; Fi cato (195% CI) iest for overail effect; Fi cato (195% CI)	 = 0.20; Heterog 244.89 286.84 = 0.94; Heterog se 215.85 < 0.00001; Heterog 779.79 < 0.00001; Heterog 	98.68 61.05 eneity: P = 695 75.07 rogeneity: Not 296.82 arogeneity: Not	35 36 71 5, P = 0 48 80 80 86 86 86 86 86 86 86 86	267.5 267.5 .07 725.76 ble 1,143.29 ble	52.96 52.96 60.67 415.5	34 36 46 46 96 96	2.8% 2.8% 5.7% 2.1% 3.0% 3.0%		-0.28 (4,76, 0.79) 0.33 (-0.14,0.80) 0.02 (-0.58, 0.63) -7.39 (-8.55, -6.24) -7.39 (-8.55, -6.24) -0.99 (-1.30, -0.68) -0.99 (-1.30, -0.68) -0.57 (-0.88, -0.24)
Labolai (95% CI) est for overall effect: F 2.3 Microscopic poly u-2021 b u-2021 b u-2021 b u-2021 b u-2021 b u-2021 b u-2021 b u-2021 b u-2021 b u-2021 d (95% CI) est for overall effect: F u-10 Kawasaki disea hen-2020 u-2021 u-2021 (95% CI) est for overall effect: F oral (95% CI)	 = 0.20; Heterog 244.69 286.64 = 0.94; Heterog se 215.85 < 0.00001; Heterog 779.79 < 0.00001; Heterog 	98.68 61.05 eneity: P = 699 75.07 rogeneity: Not 296.82 arogeneity: Not	35 38 71 5, P = 0 48 48 80 80 86 86 86 86 86 86 86 87 86 87 86 86 86 86 86 86 86 86 86 86 86 86 86	267.5 267.5 .07 725.76 ble 1,143.29 ble	52.96 52.96 60.67 415.5	34 36 46 46 96 96 3244	2.8% 2.8% 5.7% 2.1% 3.0% 3.0%	**************************************	-0.28 [-0.76, 0.79] 0.33 [-0.14, 0.80] 0.02 [-0.58, 0.63] -7.39 [-8.55, -6.24] -0.99 [-1.30, -0.68] -0.99 [-1.30, -0.68] -0.97 [-0.88, -0.26]

Figure 1. Forest plots of α -diversity richness estimators in the gut microbiota of patients with rheumatic diseases compared with healthy controls. Panel a. Observed species in patients with rheumatic diseases versus controls (n = 1,311 versus n = 994, P=0.01; inverse-variance, random-effects). Panel b. Chao 1 in patients with rheumatic diseases versus controls (n = 1,495 versus n = 3,244, P < 0.001; inverse-variance, random-effects). SD, standard deviation; CI, confidence interval.

6

a Shannon index

b Simpson	index
-----------	-------

12.1.8.7.2	
Apple Constraint Apple Constraint<	
Turnelson 1.2 <th1.2< th=""> 1.2 <th1.2< th=""> <th1.2<< td=""><td></td></th1.2<<></th1.2<></th1.2<>	
Next of the set of t	
Joney 2010 6 model 6 model 7 model	
$ \begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\$	
Line 2017 G 20 G 20 <thg 20<="" th=""> <thg 20<="" th=""></thg></thg>	
Bits 300 G 7 <thg 7<="" th=""> G 7 <thg 7<="" th=""> <thg 7<="" <="" td=""><td></td></thg></thg></thg>	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
Packate Description 2.31 0.31 11 2.30 0.71 0.72 0.75 <td>*** 0.04 (0.54), 100 (0.45), 100 (0.45</td>	*** 0.04 (0.54), 100 (0.45), 100 (0.45
Howey 2011 100 00 20 20 00 40 770 400 400 Money 2022 203 0.4 0.7 0.0 0.0 100 0.0 100 0.0 100 0.0 100 0.0 100 0.0 100 0.0 100 0.0 100 0.0 100 0.0 100	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	3.3 (10,00,00) (-0,00) -3.3 (10,00,00) (-0,00) -3.3 (10,00,00) 4.3 (10,00,00) -3.3 (10,00,00) -3.3 (10,00,00) *** -4.3 (10,00,00) -3.3 (10,00,00) *** -6.3 (10,00,00) -3.3 (10,00,00) *** -6.3 (10,00,00) -3.3 (10,00,00) *** -6.3 (10,00,00) -3.3 (10,00,00) *** -6.3 (10,00,00) -3.3 (10,00,00) *** -6.3 (10,00,00) -3.3 (10,00,00) *** -6.3 (10,00,00) -3.3 (10,00,00) *** -6.3 (10,00,00) -4.3 (10,00,00) *** -6.3 (10,00,00) -4.3 (10,00,00) *** -7.3 (10,00,00) -4.3 (10,00,00) *** -7.3 (10,00,00) -4.3 (10,00,00) *** -7.3 (10,00,00) -4.3 (10,00,00) *** -7.3 (10,00,00) -4.3 (10,00,00) *** -7.3 (10,00,00) -4.3 (10,00,00) *** -7.3 (10,00,00) -4.3 (10,00,00) *** -7.3 (10,00,00) -4.3 (10,00,00) *** -7.4 (10,00,00) -4.4 (10,00,00)
$\begin{aligned} \begin{array}{cccccccccccccccccccccccccccccccccccc$	
Balancia (pro C) 122 174 2	4 A.3.1 (A.9., A.1) 4 A.3.1 (A.9., A.1) 5 A.3.1 (A.9., A.1) 4 A.3.1 (A.9., A.1) 5 A.3.1 (A.9., A.1) 6 A.3.1 (A.9., A.1) 7 A.3.1 (A.9., A.1) 8 A.3.1 (A.9., A.1) 8 A.3.1 (A.9., A.1) 9 A.3.1 (A.9., A.1)
Table Standard Ref / F 1000, Hongong / - 05, V - 0.000 The standard Ref / F 1000, Hongong / - 05, V - 0.000 The standard Ref / F 1000, Hongong / - 05, V - 0.000 The standard Ref / F 1000, Hongong / - 05, V - 0.000 The standard Ref / F 1000, Hongong / - 05, V - 0.000 The standard Ref / F 1000, Hongong / - 05, V - 0.000 The standard Ref / F 1000, Hongong / - 05, V - 0.000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 05, V - 0000 The standard Ref / F 1000, Hongong / - 0000, Hongong / - 0000	
Company 3 3 3 4 3 4 3 6 4 3 6 4 3 6 4 3 7 6 7 </td <td></td>	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	- 1.2 (12), 0.6
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	
Since of the second s	
$\begin{split} \begin{array}{cccccccccccccccccccccccccccccccccccc$	
Damp 2010 2.77 0.01 0.24 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01	
Array Constraints All B B	** - 2.20 (gr. Action 400) ** - 2.20 (gr. Action 400) ** - 2.20 (gr. Action 400) ** - 4.20 (gr. Action 400) ** - 4
Linking reg Char Linking reg Linking reg <thl< td=""><td></td></thl<>	
Table Server Market Pri - 1921; Hanney Market Pri - 1920; Hanney Market P	4.34 (6.40, 0.27) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.67) -1.17 (-1.60, 0.77) -1.17 (-1.60, 0.77) -1.17 (-1.60, 0.77) -1.17 (-1.60, 0.77) -1.17 (-1.60, 0.77) -1.17 (-1.10, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77) -1.17 (-1.17, 0.77)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	
Cano Ober 2021 6 2 1 1 2 2 1 6 1 1 2 2 6 1 2 1 1 2 2 6 1 2 1 1 2 1 2	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	***
Main-Tori 4.2 0.2 0.2 0.4 0.7 0.2 0.7 <th0.7< th=""> <th0.7< td=""><td></td></th0.7<></th0.7<>	
Number 1.3 0.4 <th0.4< th=""> <th0.4< t<="" td=""><td></td></th0.4<></th0.4<>	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	- diag (1420, 001) - diag (
Babase BOP Characterization 122 128 126<	
$\begin{array}{c} \text{the constraints} \begin{tabular}{ c c c c } & \text{the constraints} \begin{tabular}{ c c c c c } & \text{the constraints} \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
Bubble Model S5 B2 27 77 08 27 97 08 17 07 08 17 07 08 17 07 08 17 07 08 17 07 08 17 07 08 17 07 08 17 07 08 17 07 08 17 07	
Chard-2011** 2.86 0.81 171 2.97 0.8 192 4.90	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	
Dubbeller Dubbeller	→ 20 (1 ≤ 10, 0.2) → 20 (1
$\begin{tabular}{ c c c c c } \hline $L_{10} $ $L_{10} $L_$	
Builden (B) C_1 20 20 20 20 20 20 20 20 45 43 45 Addesson 2020 57 0.3 10 <td< td=""><td></td></td<>	
ten a La manager 1 - 2002, Heregoregraph + 2 - 2 - 2010 La mage 2011 - 4 - 20 - 20 - 20 - 20 - 20 - 20 - 20	O 27 (5 28, 0 04) O 28 (5 0, 1 37) O 28 (5 0, 2 34) O 28 (5 0, 2
$\begin{array}{c} \begin{tabular}{lllllllllllllllllllllllllllllllllll$	• 0 0 75 83.0 081 • 0 0 10 10 10 10 10 10 10 10 10 10 10 10
Lam-2011 4 42 0 48 19 44 04 0 80 19 50 50 50 19 10 10 10 10 10 10 10 10 10 10 10 10 10	** 0 0 0 0 0 1 1 7 7 0 0 0 0 0 1 7 7 4 2 0 0 0 2 0 1 7 7 4 2 0 0 0 2 0 1 7 7 4 2 0 0 0 2 0 1 7 7 4 2 0 0 0 2 0 1 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 4 4 1 2 4 0 2 0 1 0 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8
Larm 0.01 D.2 D.3 D.3 D.4 D.0 D.3 D.4 D.0 D.0 D.4 D.0 D.0 D.4 D.0 D.0 D.4 D.0 D.0 <thd.0< th=""> D.0 <thd.0< th=""> <thd.0<< td=""><td></td></thd.0<<></thd.0<></thd.0<>	
Linker (c) Linker (c) <thlinker (c)<="" th=""> Linker (c) Linker (</thlinker>	122 (54), 241 122 (54), 241 122 (54), 241 122 (54), 241 122 (54), 241 124 (54), 513 124 (54), 514 124 (54), 514 124 (54), 514 124 (54), 514 124 (54), 514 124 (54), 514 124 (54), 514 124 (54), 514 124 (54), 514 124 124 (54), 514 124
The for even det $P = 0.51$, Heregroups $P = 0.85$, $P < 0.0001$ Hard Det $P = 0.05$, Heregroups $P = 0.85$, $P < 0.0001$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P < 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P < 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P < 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P < 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P < 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P < 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P < 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P < 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P < 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$, Heregroups $P = 0.05$ Hard Det $P = 0.05$, Heregroups $P = 0.05$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	C 2 1 (2 30 2 7 31 2 37 31 2 4 (2 4 7 7 1 7 1 7 1 7 1 2 4 2 7 1 4 2 3 7 1 7 1 2 4 1
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
State-Sign 1.1 0.0 7 2.2 0.0 9 0.0 ************************************	- 4.86 (4.80, 1.00 - 4.17 (4.46, 5.37) - 4.28 (4.38, 1.00 - 4.28 (4.38, 1.00 - 4.28 (4.38, 1.00 - 4.17 (4.13, 0.01 - 4.17 (4.15, 0.05) - 4.17 (4.45, 0.01 - 4.17 (4.45, 0.01) - 4.17 (4.45, 0
animum prod. 1 0 3.6 3.6	- 4.4 (346, 53) - 4.37 (347, 537) - 4.17 (422, 617) - 7.37 - 4.17 (246, 58) - 4
1.3 P Resemption 1.2 P Resemptio	- 0.20 (0.00, 0.00) - 0.32 (0.50, 0.10) - 0.32 (0.53, 0.17) - 0.10 (0.15, 0.50) - 0.10 (0.55, 0.17) - 0.11 (0.56, 0.50) - 0.21 (0.20, 0.65) - 0.21 (0.20, 0.55) - 0.21 (0.20, 0.25) - 0.21 (0.20, 0.25) - 0.21 (0.20, 0.25) - 0.21 (0.20, 0.25) - 0.21 (0
De-Gampa)11 4 72 0 00 100 400 00 40 000 40 100 00 40 100 40 000 40 100 40 000 40 100 4	-0.28 (0.08, 0.09) -0.38 (0.38, 0.19) -0.19 (0.13, 0.09) -0.19 (0.13, 0.09) -0.19 (0.13, 0.09) -0.19 (0.09, 0.08) -0.11 (0.09, 0.38) -0.11 (0.09, 0.38) -0.14 (0.37, 1.73) -1.52 (0.28, 0.08) -0.00 (0.08, 0.06)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	- 3.38 (4.38, 4.518) - 4.37 (4.32, 4.57) - 4.37 (4.32, 4.17) - 4.37 (4.32, 4.17) - 4.37 (4.32, 4.17) - 4.37 (4.32, 6.38) - 4.37 (4.33, 6.38) - 4.37 (
minimum cpc, Like up, minimum cpc,	0.11 (v.1.5, 0.00) 0.11 (v.0.2, 0.17) 1.04 (1.57, 0.51) 0.11 (1.69, 0.39) 2.44 (3.17, -1.71) 1.17 (2.40, 0.06) 0.03 (1.69, 0.66) 0.03 (1.69, 0.66)
$\begin{tabular}{ c c c c c } Table (Control (C$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	-1.04 [-1.57, -0.51] -0.11 [-0.59, 0.39] -2.44 [-3.17, -1.77] -1.17 [-2.40, 0.06]
Linearies Second T	0.01(-0.9, 0.03) -0.11(-0.9, 0.30] -0.44(-0.17, -1.71] -1.17(-2.40, 0.06) -0.03(-0.60, 0.66)
Back-2017 5.49 1.00 201 1.02 2.44 4.74 1.13 Streament IP - 5.00 Streament I	-2.44 [3.17, -1.71] -1.17 [2.46, 0.06]
andmain proc Quine Quine 9 10 4.5% 1.17 andmain proc Quine 3.31 0.7 3.32 0.7 1.5% 1.6% Ageneral Science Arriter 3.31 0.7 3.32 0.7 1.5% 1.6% Ageneral Science Arriter 3.31 0.7 3.32 0.7 1.5% 1.6% Ageneral Science Arriter 1.2 3.25 0.7 1.6% 1.6% 1.6% Ageneral Science Arriter 2.31 0.3 3.7 2.5 0.8 9.8% 4.64 Manual Science Arriter 2.20 0.7 3.7 0.7 1.7% 4.24 Manual Science Arriter 2.31 0.8 2.5 0.6 1.6% 4.24 More 2011 3.0 2.5 0.6 1.6% 4.7% 4.24 More 2011 3.0 2.5 0.6 1.6% 1.7% 4.22 Total Science Arriter Arriter 2.00 3.4 1.7% 4.24 More 2011 3.4<	-1.17 [-2.40, 0.06]
1 = 1 1 = 0 1 = 0 1 = 0 1 = 0 0	0.03 (-0.60, 0.65) -0.43 (-0.67, 0.01)
Agginumedari 3,1 0,7 31,30 0,7 10,50 *** 0,00 Generation 10,75 37,40 7,7 31,20 0,7 10,70 10,7	0.03 (-0.60, 0.65)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	-0.43 60.87 0.011
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	-0.00 [0.00]
Tart for small starting for 216, P = 0.02 To To </td <td>0.48 [0.01, 0.94]</td>	0.48 [0.01, 0.94]
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
Number Numbe	-0.47 [-0.84, -0.10]
Balance (MS C) 12 10 11 10	* 0.22 [-0.02, 0.45]
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	-0.23 [-0.73, 0.27]
La li manone popymenti La m	
Vp20275 4/20 0.05 34 512 0.07 34 10% 1	
Builden (BV C) 7 7 8 3.4% 4.04 Builden (BV C) 7 7.8% 7.6% 4.04 4.04 Builden (BV C) 3.44 0.2 5.3.46 0.41 1.0% 4.03 Builden (BV C) 3.44 0.2 5.0 0.04 1.0% 4.03 Builden (BV C) 3.24 0.2 0.4 0.0 0.1 4.0 4.05 4.03 Builden (BV C) 3.24 0.2 0.4 0.0 0.1 4.0 4.05 4.00 4.00 4.00 4.00 4.00 3.07 4.00 3.07 4.00 3.07 4.00 4.00 0.1 4.00 3.07 3.07 3.07 3.07 3.07 3.07 4.00 4.00 0.1 4.00 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07 3.07<	-0.28 [-0.75, 0.19]
Tail for Variant day 1** 0.027; Hendrighen 1** 2**15; *** 0.23	-0.48 [-0.89, -0.07]
1.3.12 (j.4.4.1) 2.4.1 0.2.5 0.4.1 0.5.1 0.4.1	
Instruction (C) Interview (C) Inter	*
Text for under detter, P = 0.001: heterogeneity, Net applicable	 0.50 [-0.80, -0.19] 0.50 [-0.80, -0.19]
1.3.15 (see and sec as a	
americani 3.32 0.72 45 5.99 0.81 46 10% -1.4 -3.07 Modelad (DS) 0.0001 Helengenety, Not applicable -3.07 -3.07 -3.07 Text for unreal effect: P<0.0001	
Test for overall effect: P < 0.0000 * Heterogenetity: Hot applicable 13.14 Parallel anthrhitis 5chre 2015 2.85 0.19 16 3.49 0.15 17 1.0% Subtract 105 x C(t) 2.85 0.19 16 3.49 0.15 17 1.0% Subtract 105 x C(t) 16 17 1.6% -3.66 -3.66	-3.07 [-3.68, -2.47] -3.07 [-3.68, -2.47]
1.3.14 Parintilic arthritis 1.3.14 Parintic	
Scherz016 2,85 0.19 16 3,49 0.15 17 1,0%	
Test for overall effect: P < 0.00001: Heterogeneity: Not applicable	-3.66 [-4.62, -2.50]
The second s	-3.00 [-0.02, -2.50]
Total (95% Cl) 2893 7444 100.0%	+
Test for micral effect: P < 0.0001; Helemanely: P = 07%, P < 0.00001	-0.33 [-0.46, -0.17]

	Expe	eriment	al	С	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.4.1 Ankylosing spor	ndylitis			0.0	0.00	20	0.00		0.407.000.004
Chen 2021	0.00	0.11	41	0.9	0.00	32	3.6%	-+-	-0.43 [-0.90, 0.04]
G101-2021	0.93	0.05	30	0.90	0.02	20	3.170	-+-	-0.72 [-1.31, -0.12]
Lin 2020	0.5	0.03	10	0.07	0.04	12	2.2%		0.04 [0.10, 1.13]
Wep-2017	0.13	0.03	97	0.61	0.01	114	1 196		0.06 (-0.21 0.33)
Zhang 2019	0.02	0.10	102	0.01	0.15	105	4.4%	-	0.00[-0.21, 0.33]
Subtotal (95% CI)	0.10	0.00	322	0.14	0.1	312	21.3%	+	-0.12 [-0.47, 0.23]
Test for overall effect: F	e = 0.50;	Heterop	eneity	² = 75	%, P =	0.001			
4.4.0.01									
1.4.2 Kneumatoid arth	Initis	0.00		0.00	0.00	00	0.00/		0.001450.007
Forbes-2018	0.87	0.09	21	0.93	0.03	23	3.0%		-0.90 [-1.52, -0.27]
He-2022	0.86	0.1	205	0.01	0.05	100	3.4%		0.10 [-0.44, 0.63]
Seber 2012	0.9	0.00	200	0.91	0.00	26	2.5%		0.40 [0.00 0.00]
Wang-2022*	0.88	0.06	108	0.9	0.05	99	4.4%		-0.36 [-0.63 -0.08]
Subtotal (95% CI)			403			376	18.9%	•	-0.31 [-0.54, -0.08]
Test for overall effect: F	e = 0.007	; Hetero	geneit	y: 2 = 4	18%, P	= 0.10			
4.4.2.0									
1.4.3 Gout	40.00			40.00	0.50		4 4 60	- 41	0.0011.000.0073
Chu-2021	10.00	0.41		10.98	0.52	63	4.1%		-0.69 [-1.03, -0.35]
Móndoz-Salazar 2021	0.56	0.15	25	0.07	0.04	20	3.4%	-+-	-0.92 [-1.44, -0.39]
Shao.2017	0.80	0.02	26	0.85	0.03	26	3.2%	-+-	-1.03 [-1.61 -0.45]
Subtotal (95% CI)	0.00	0.00	166	0.00	0.00	168	14.3%	•	-0.64 [-1.07, -0.22]
Test for overall effect: F	e = 0.003	Hetero	aeneit	v: 2 = 6	9%. P	= 0.02			
1.4.4 Sjögren syndron	ne								
Cano-Ortiz-2020	0.79	0.05	19	0.84	0.07	19	2.9%		-0.80 [-1.47, -0.14]
Wang-2020 a	0.08	0.01	9	0.14	0.02	10	1.0%		-3.56 [-5.12, -2.00]
Wang-2020 b	0.17	0.02	9	0.14	0.02	10	1.8%		1.43 [0.40, 2.47]
Tost for overall offect: E	2 - 0.44-1	Hotorog	onoitu	B < 01	00001	- 12 - 0 ⁴	30.7 /0		-0.50 [-5.10, 1.57]
Test for overall effect. I	- 0.44,1	necerog	onony.	1 5 0.	00001)	, i = av	,,,,		
1.4.5 Fibromyalgia									
Clos-Garcia-2019	0.93	0.03	105	0.94	0.02	54	4.2%		-0.37 [-0.70, -0.04]
Freidin-2021	0.93	0.05	113	0.94	0.04	1623	4.6%	,	-0.25 [-0.44, -0.05]
Subtotal (95% CI)			218			16//	8.8%	Y	-0.28 [-0.44, -0.11]
l est for overall effect: F	² = 0.001;	; Hetero	geneit	y: 1² = 0	7%, P =	= 0.53			
1.4.6 Microscopic poly	yangiitis								
Yu-2021 a	0.9	0.05	35	0.94	0.03	34	3.5%	- + -	-0.96 [-1.46, -0.46]
Yu-2021 b	0.91	0.06	36	0.94	0.03	34	3.6%		-0.62 [-1.10, -0.14]
Subtotal (95% CI)			71			68	7.1%	•	-0.78 [-1.13, -0.44]
Test for overall effect: F	o < 0.000	01; Het	eroger	ieity: l²	= 0%,	P = 0.3	4		
1.4.7 Systemic lupus	ervthema	atosus							
He-2020	0.11	0.01	21	0.1	0.01	10	2.4%		0.97 [0.18, 1.77]
Liu-2021*	0.19	0.19	35	0.28	0.02	35	3.6%	- + -	-0.66 [-1.14, -0.18]
Subtotal (95% CI)			56			45	6.0%	-	0.13 [-1.47, 1.72]
Test for overall effect: F	e = 0.88;	Heteroş	eneity	: l² = 92	%, P =	= 0.000	6		
1.4.9 Sustamia aslara	ala								
1.4.6 Systemic sclero: Patrono 2017 a	0.02	0.02	c	0.04	0.04	0	2.08	_+	0.6014.66.0.25
Patrone-2017 a	0.03	0.02	9	0.04	0.01	9	1.0%		-0.60 [-1.55, 0.35]
Subtotal (95% CI)	0.08	0.03	18	0.04	0.01	18	3.7%		0.53 [-1.73, 2.79]
Test for overall effect: F	P = 0.65	Heterroo	eneitv	1 ² = 89	% P =	: 0.002	70		
				50					
1.4.9 IgG4-related dise	eases								
Liu-2021	0.93	0.04	34	0.95	0.02	64	3.8%		-0.70 [-1.12, -0.27]
Subtotal (95% CI)			34			64	3.8%		-0.70 [-1.12, -0.27]
Test for overall effect: F	² = 0.001;	Hetero	geneit	y: Not a	applical	ble			
1.4.10 Juvenile idiopa	thic arth	ritis							
Aggarwal-2017	0.9	0.08	33	0.91	0.05	14	3.0%		-0.14 [-0.76, 0.49]
Subtotal (95% CI)			33			14	3.0%	•	-0.14 [-0.76, 0.49]
Test for overall effect: F	° = 0.67;	Hetero	geneity	: Not a	pplicab	le			
1.4.11 Osteoarthritie									
Wang-2021	0.11	0.00	86	0.09	0.06	96	4 3%		0.26 (-0.03, 0.56)
Subtotal (95% CI)	0.11	5.00	86	0.08	5.00	96	4.3%	•	0.26 [-0.03, 0.56]
Test for overall effect: F	> = 0.08:	Heteroo	eneitv	Not as	oplicab	le			
11100 10 10									
1.4.12 Psoriatic arthrif	us -								
Scher-2013 Subtotal (95%, Ch	0.87	0.04	16	0.9	0.08	26	3.0%	-	-0.43 [-1.06, 0.20]
Test for overall effect: F	2 - 0.18-	Hotoro	01 Hinner	· Not a	onliceb	20 Ja	3.0%	-	-0.43 [-1.00, 0.20]
rest for overall effect. F	- 0.18;	netero	Joneity	. NOL 8	ppiical0	nu			
Total (95% CI)			1460			2903	100.0%	+	-0.32 [-0.49, -0.14]
Test for overall effect: P	e = 0.000	4; Hete	rogene	ity: I² =	79%, F	P < 0.0	0001 -	4 2 0 2	
								Decreased Increased	-

Figure 2. Forest plots of α -diversity richness/evenness in the gut microbiota of patients with rheumatic diseases compared with healthy controls. Panel a. Shannon index in patients with rheumatic diseases versus controls (n = 2,893 versus n = 7,444, P < 0.001; inverse-variance, random-effects). Panel b. Simpson index in patients with rheumatic diseases versus controls (n = 2,903, P < 0.001; inverse-variance, random-effects). SD, standard deviation; CI, confidence interval.

v



Figure 3. β-diversity comparison between patients with rheumatic diseases and healthy controls. RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; AS, ankylosing spondylitis; SS, systemic sclerosis; JIA, juvenile idiopathic arthritis; OA, osteoarthritis; FM, fibromyalgia; KD, Kawasaki disease; MPA, microscopic polyangiitis; PsA, psoriatic arthritis; IgG4-D, IgG4-related diseases; BD, Behcet's disease; SJS, Sjögren's syndrome.

8

lupus erythematosus, systemic sclerosis, ankylosing spondylitis, gout, Sjögren's syndrome and IgG4-related diseases) reported significant difference of β -diversity. Among these diseases, consistently different β -diversity was only reported in ankylosing spondylitis and IgG4-related diseases.

Differentially abundant microbes

Seventy-four studies examined the relative abundance of gut microbes in patients with rheumatic diseases versus controls at phylum, family, or genus levels. Differences spanning II phyla, 23 families, and II2 genera were observed. The study-level findings can be found in **Appendix 12** and **Supplementary Tables 1–3**.

Figure 4 summarises the within and across rheumatic disease comparison for the microbes reported by two or more studies. A high within disease inconsistency was observed, and most of the consistent within disease changes were replicated by only 2 studies, suggesting that there is little evidence for disease-specific alteration regarding relative abundance of gut microbes. Instead, our findings indicate a shared alteration across multiple rheumatic diseases for certain microbes. The most consistent changes were the enrichment of Streptococcus in ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis (20 of 21 studies reported this genus) and Lactobacillus in ankylosing spondylitis, systemic lupus erythematosus and systemic sclerosis (11 of 11 studies). We also observed the depletion of Faecalibacterium in rheumatoid arthritis, Sjögren's syndrome and systemic lupus erythematosus (8 of 9 studies).

Discussion

This study assessed gut microbiota alterations across a spectrum of rheumatic diseases through a systematic review and meta-analysis. The main findings were: (1) small to moderate decreases in α -diversity indices were found consistently in rheumatic diseases taken as a whole. When specific rheumatic diseases were examined, decreases in α -diversity were only observed in rheumatoid arthritis, systemic lupus erythematosus, gout, and fibromyalgia; whereas an increase was observed in systemic sclerosis; (2) significant differences of β -diversity were frequently reported in a qualitative manner but only consistently in ankylosing spondylitis and IgG4-related diseases; (3) patients with rheumatoid arthritis, Sjögren's syndrome and systemic lupus erythematosus shared the alterations of the depletion of anti-inflammatory butyrate-producing microbe (i.e., Faecalibacterium) and the enrichment of proinflammatory microbe (i.e., Streptococcus); (4) whenever gut microbes merited specificity, these alterations were weakly reproduced, suggesting that disease-specific alterations remain uncertain and thus need further verification.

A meta-analysis which included 28 case-control gut microbiome studies involving 10 diseases (i.e., diarrhea, colorectal cancer, inflammatory bowel disease, obesity, human immunodeficiency virus, autism spectrum disorder, type I diabetes, liver diseases, arthritis, Parkinson's disease) indicated that many associations were likely to be non-disease-specific but rather part of a non-specific, shared alteration to health and disease.34 Several systematic reviews on gut dysbiosis in specific rheumatic diseases have been published.41-44 Of these, Chu et al. analysed 26 case-control studies and found that either decreased or unchanged α -diversity was commonly seen in patients with rheumatoid arthritis, and the depletion of genus Faecalibacterium was also reported frequently in such patients.⁴³ The review by Wang et al., including 14 case-control studies, reported a remarkably increased α -diversity in patients with ankylosing spondylitis, accompanied by increased amounts of genus Dialister and Streptococcus as well as decreased amounts of genus Parasutterella.44 The remaining two reviews concluded that the gut microbiota in patients with psoriatic arthritis⁴² and fibromyalgia⁴¹ was different from that in controls, but the findings were heterogeneous. In our study, we included 92 observational studies spanning 14 rheumatic diseases and revealed that gut microbiota dysbiosis was associated with rheumatic diseases in general with predominantly non-specific, shared alterations of microbes.

While it is challenging to establish the causal relationship between gut dysbiosis and the risk of rheumatic diseases based on case-control studies or crosssectional studies,¹⁰ experimental evidence indicated that gut dysbiosis could lead to changes in systemic immune responses, loss of tolerance and development of autoimmunity.^{45–47} Data derived from animal models,⁴⁸ results obtained from patients with early-stage diseases,⁴⁹ and findings generated from causal analytical approaches (e.g., Mendelian randomization and polygenic risk score)^{50,51} also suggested that gut dysbiosis might precede the onset of disease and somehow act as a concealed trigger for systemic inflammation.

The biological mechanisms linking gut dysbiosis to systemic inflammation have been postulated. The gut epithelial cells can form a dynamic physical barrier to strictly control antigen trafficking through paracellular pathways. However, the barrier integrity of the gut may be breached by zonulin production following the development of gut dysbiosis, causing disassembly of tight junction proteins.^{52–54} This phenomenon had been reported in patients with rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus and other rheumatic diseases.^{48,55–59} Abnormal gut barrier function may result in increased epithelial permeability, allowing microbial fragments and products to enter the sub-epithelial space and lamina propria.⁶⁰ Upon



Figure 4. Changes in relative abundance of microbes reported by at least two studies from a diagnostic category. AS, ankylosing spondylitis; BD, Behcet's disease; JIA, juvenile idiopathic arthritis; OA, osteoarthritis; RA, rheumatoid arthritis; SjS, Sjögren's syndrome; SLE, systemic lupus erythematosus; SS, systemic sclerosis.

binding to specific receptors of antigen-presenting cells, these molecules will activate pro-inflammatory T cells (including T helper 1 and T helper 17 cells), thus inducing B cells to differentiate into autoantibody-producing plasma cells. At the same time, under the condition of protective molecules, the anti-inflammatory pathway will be activated, and the regulatory T cells will be polarized afterwards.⁶¹ These immune cells primed in the gut can traffic to other organs and tissues.48,62,63 For example, the synovium of patients with rheumatoid arthritis contains T cells in expression of the gut homing receptor $\alpha E\beta_7$ integrin.⁶⁴ Once trafficking to target organs or tissues, the immune cells and their products will activate macrophages, release pro-inflammatory cytokines, or inactivate the inflammatory pathway by producing anti-inflammatory cytokines.¹⁰ Taken together, in case that pathobiont microbes occupy a predominant position, a persistent chronic inflammatory condition will be likely to induce the occurrence or development of rheumatic diseases.²⁷

Short-chain fatty acids (SCFAs), which are generated by the bacterial metabolism of dietary elements, exert a direct function of immunomodulation.⁶⁵ Studies have found that SCFAs have an effect on both anti-inflammation and promoting bone formation, through which they could reduce the risk or improve the prognosis of rheumatic diseases including rheumatoid arthritis, gout and ankylosing spondylitis.^{66–71} It has been established that *Faecalibacterium* possesses anti-inflammatory properties⁷² and will be depleted in some immune-mediated inflammatory diseases (e.g., Crohn's disease and inflammatory bowel disease).^{73,74} Such associations may be mediated by the SCFA butyrate, as *Faecalibacterium* plays a role in its production.⁷⁵ Butyrate is critically involved in maintaining the mucosal integrity, alleviating inflammation (through the macrophage function and a decrease in proinflammatory cytokines), and increasing anti-inflammatory mediators.75-77 Also the well-known pro-inflammatory microbe Streptococcus has been linked to inflammatory pain disorders, such as osteomyelitis,78,79 rheumatic fever^{80,81} and post-streptococcal reactive arthritis.^{82,83} Metabolites and membrane vesicles produced by Streptococcus can penetrate the gut-blood barrier and enter the general circulation so as to activate macrophages to pro-inflammatory macrophages; this may trigger a systemic inflammatory status at a low grade, causing or exacerbating the inflammation and damage to human body.⁸⁴ Interestingly, we observed that Lactobacillus, classically considered as a beneficial commensal genus and inversely related to inflammatory states,⁸⁵ was also enriched across multiple rheumatic diseases. This phenomenon might be explained by the activation of different components of the immune response in rheumatic diseases by species from this genus.⁸⁶

We provided comprehensive evidence by assessing gut microbiota alterations across a wide range of rheumatic diseases through a systematic review and metaanalysis including 92 observational studies with 11,998 participants. Our results showed a comprehensive overview of current evidence regarding the microbial diversity, disease-specific and shared alterations of gut microbes. In addition, all included studies were human observational studies, so the results may have implications of clinical relevance. However, limitations of this study should also be sincerely pointed out. Firstly, most of the included studies were of a modest sample size; thus, our analyses might still be underpowered and preliminary, and require further verification with studies of larger sample sizes. Secondly, substantial heterogeneity was observed in the meta-analysis. When more evidence becomes available, additional analyses are required to identify the sources of heterogeneity. For example, there is evidence that microbial composition varied in different disease statuses (active versus inactive)⁸⁷ and dura-(i.e., newly diagnosed versus previously tions diagnosed).⁸⁸ Thirdly, this study aimed to examined the gut microbial composition rather than its function, whereas previous evidence implied that functional potentials related to rheumatic diseases, such as SCFAs synthesis,⁸⁹ tryptophan and lipoprotein metabolism, may be important in pathogenesis.^{90,91} In view of the noted functional redundancy,92 the role of gut microbiota in rheumatic diseases should be further elucidated by functional analysis. Fourthly, our qualitative summary of gut microbes may suffer from different computational pipelines that were used to analyse the microbiome community. When more published raw data become available, future meta-analyses using standard processing and analysis methods are warranted to compare gut microbes across different studies. Finally, the gut microbiota among most of the included studies was profiled by 16s rRNA gene sequencing. This technique is not capable of pinpointing any specific microbial species and strains, so it is still not clear whether the species or strains of Faecalibacterium, Streptococcus or Lactobacillus are shared across rheumatic diseases. Thus, further metagenomic studies are expected to identify the specific species or strains of these genera.

Sufficient microbial diversity lays the foundation in creating good adaptability and enhanced resistibility for the gut microbiota in case of environmental challenges. Reduced diversity may provide a favourable condition for the emergence of pathogenic microbes, which can disrupt the gut barrier and promote the production of inflammatory mediators through mucosal epithelial cells in the intestinal lamina propria and mesenteric lymph nodes.⁹³ Our meta-analysis revealed that α -diversity was significantly reduced in patients with rheumatic diseases, which provides a helpful framework to form hypotheses for further studies on the associations between rheumatic diseases and gut microbiota. Since the results were mainly driven by studies from Eastern countries, it might be necessary to distinguish the Eastern microbiota from other Western nations as new evidence becomes available. Also, decrease of the α -diversity indices was mainly seen in studies where patients did not receive any treatments, suggesting that decreased microbial diversity in rheumatic diseases may be relieved by antirheumatic treatment.^{13,54} However, when specific rheumatic diseases were examined, decrease in microbial diversity was only observed in rheumatoid arthritis, systemic lupus erythematosus, gout and fibromyalgia. It is worth noting that a

significant increase, meanwhile, was observed in systemic sclerosis. This surprising finding suggests a more heterogenic gut microbial compositional profile in patients with this disease.

We also found that alterations in some microbes (i.e., *Faecalibacterium, Lactobacillus, Streptococcus*) may be associated consistently with multiple rheumatic diseases. This suggests that many identified microbial associations might indicate a shared alteration to multiple rheumatic diseases rather than a disease-specific biological difference, so the included studies should be interpreted cautiously. These microbes and their metabolites could also be used as general targets for innovative preventive or therapeutic tools for different rheumatic diseases. Finally, little evidence of distinct disease-specific alterations in gut microbes was evident. This suggests that gut microbes serving as diagnostics for specific rheumatic diseases warrants further investigations.

In conclusion, gut microbiota dysbiosis was associated with rheumatic diseases, principally with potentially non-specific, shared alterations of microbes.

Contributors

Chao Zeng and Guanghua Lei had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Chao Zeng, Guanghua Lei, Yilun Wang and Jie Wei. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Yilun Wang, Jie Wei, Chao Zeng and Guanghua Lei. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Yilun Wang and Jie Wei. Obtained funding: Chao Zeng, Guanghua Lei and Jie Wei. Administrative, technical, or material support: Chao Zeng and Guanghua Lei. Supervision: Chao Zeng and Guanghua Lei. All authors have read, provided critical feedback on intellectual content and approved the final manuscript. The interpretation of these data is the sole responsibility of the authors.

Declaration of interests

No conflict of interest for any of the authors.

Data sharing statement

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Acknowledgements

Everyone who contributed significantly to the work has been listed. This work was supported by the National Natural Science Foundation of China (81930071, 81902265, 82072502, U21A20352). No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j. ebiom.2022.104055.

References

- I Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. *Nat Med.* 2018;24(4):392-400.
- 2 Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13 (5):321-335.
- 3 Clemente JC, Manasson J, Scher JU. The role of the gut microbiome in systemic inflammatory disease. *BMJ*. 2018;360:j5145.
- 4 Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. *Science*. 2006;312(5778):1355–1359.
- 5 Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. *Nature*. 2009;457(7228):480–484.
- 6 Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature*. 2012;490(7418):55-60.
- 7 Karlsson CL, Onnerfalt J, Xu J, Molin G, Ahrne S, Thorngren-Jerneck K. The microbiota of the gut in preschool children with normal and excessive body weight. *Obesity*. 2012;20(11):2257–2261. (Silver Spring).
- 8 Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070–11075.
- 9 Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013;500 (7464):541-546.
- Io Van de Wiele T, Van Praet JT, Marzorati M, Drennan MB, Elewaut D. How the microbiota shapes rheumatic diseases. Nat Rev Rheumatol. 2016;12(7):398-411.
- II Alpizar-Rodriguez D, Lesker TR, Gronow A, et al. Prevotella copri in individuals at risk for rheumatoid arthritis. Ann Rheum Dis. 2019;78(5):590-593.
- 12 Kishikawa T, Maeda Y, Nii T, et al. Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. *Ann Rheum Dis.* 2020;79 (I):103–111.
- 13 Zhang X, Zhang D, Jia H, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015;21(8):895–905.
- I4 Breban M, Tap J, Leboime A, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;76 (9):1614–1622.
- 15 Yin J, Sternes PR, Wang M, et al. Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann Rheum Dis. 2020;79 (1):132–140.
- Tomofuji Y, Maeda Y, Oguro-Igashira E, et al. Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese. *Ann Rheum Dis.* 2021;80(12):1575–1583.
 Chen BD, Jia XM, Xu JY, et al. An autoimmunogenic and proin-
- 17 Chen BD, Jia XM, Xu JY, et al. An autoimmunogenic and proinflammatory profile defined by the gut microbiota of patients with untreated systemic lupus erythematosus. *Arthritis Rheumatol.* 2021;73(2):232-243.
- 18 Volkmann ER, Chang YL, Barroso N, et al. Association of systemic sclerosis with a unique colonic microbial consortium. Arthritis Rheumatol. 2016;68(6):1483–1492.
- 19 Plichta DR, Somani J, Pichaud M, et al. Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. *Genome Med.* 2021;13(1):35.
- 20 Mandl T, Marsal J, Olsson P, Ohlsson B, Andreasson K. Severe intestinal dysbiosis is prevalent in primary Sjogren's syndrome and is associated with systemic disease activity. Arthritis Res Ther. 2017;19(1):237.
- 21 van der Meulen TA, Harmsen HJM, Vila AV, et al. Shared gut, but distinct oral microbiota composition in primary Sjogren's syndrome and systemic lupus erythematosus. J Autoimmun. 2019;97:77–87.

- 22 Huang Z, Chen J, Li B, et al. Faecal microbiota transplantation from metabolically compromised human donors accelerates osteoarthritis in mice. Ann Rheum Dis. 2020;79(5):646–656.
- 23 Wei J, Zhang C, Zhang Y, et al. Association between gut microbiota and symptomatic hand osteoarthritis: data from the Xiangya osteoarthritis study. Arthritis Rheumatol. 2021;73(9):1656–1662.
- Rosenbaum JT, Asquith MJ. The microbiome: a revolution in treatment for rheumatic diseases? *Curr Rheumatol Rep.* 2016;18(10):62.
 Shreiner AB, Kao JY, Young VB. The gut microbiome in health and
- in disease. Curr Opin Gastroenterol. 2015;31(1):69–75.
- 26 Bao Y, Dong C, Ji J, Gu Z. Dysregulation of gut microbiome is linked to disease activity of rheumatic diseases. *Clin Rheumatol.* 2020;39(9):2523–2528.
- 27 Zhong D, Wu C, Zeng X, Wang Q. The role of gut microbiota in the pathogenesis of rheumatic diseases. *Clin Rheumatol.* 2018;37 (1):25-34.
- 28 Shade A. Diversity is the question, not the answer. *ISME J.* 2017;11 (1):1–6.
- 29 Guo M, Wang H, Xu S, et al. Alteration in gut microbiota is associated with dysregulation of cytokines and glucocorticoid therapy in systemic lupus erythematosus. *Gut Microbes*. 2020;11(6):1758– 1773.
- 30 Li Y, Wang HF, Li X, et al. Disordered intestinal microbes are associated with the activity of systemic lupus erythematosus. *Clin Sci.* 2019;133(7):821–838. (Lond).
- 31 Zhang F, Ma C, Zhang B, Bi L. Dynamic changes in gut microbiota under the influence of smoking and TNF-alpha-blocker in patients with ankylosing spondylitis. *Clin Rheumatol.* 2020;39(9):2653– 2661.
- 32 Chen Z, Zheng X, Wu X, et al. Adalimumab therapy restores the gut microbiota in patients with ankylosing spondylitis. *Front Immunol.* 2021;12: 700570.
- 33 Olesen SW, Alm EJ. Dysbiosis is not an answer. Nat Microbiol. 2016;1:16228.
- 34 Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. *Nat Commun.* 2017;8(1):1784.
- 35 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
- 36 Nikolova VL, Smith MRB, Hall LJ, Cleare AJ, Stone JM, Young AH. Perturbations in gut microbiota composition in psychiatric disorders: a review and meta-analysis. JAMA Psychiatry. 2021;78 (12):1343–1354.
- 37 The Cochrane Collaboration,. Cochrane Handbook For Systematic Reviews of Interventions. Wiley; 2011.
- 38 Bechard LJ, Rothpletz-Puglia P, Touger-Decker R, Duggan C, Mehta NM. Influence of obesity on clinical outcomes in hospitalized children: a systematic review. JAMA Pediatr. 2013;167(5): 476-482.
- 39 Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
- 40 Higgins D. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2008.
- 41 Erdrich S, Hawrelak JA, Myers SP, Harnett JE. Determining the association between fibromyalgia, the gut microbiome and its biomarkers: a systematic review. BMC Musculoskelet Disord. 2020;21(1):181.
- 42 Todberg T, Kaiser H, Zachariae C, Egeberg A, Halling AS, Skov L. Characterization of the oral and gut microbiota in patients with psoriatic diseases: a systematic review. *Acta Derm Venereol.* 2021;101(7):adv00512.
- 43 Chu XJ, Cao NW, Zhou HY, et al. The oral and gut microbiome in rheumatoid arthritis patients: a systematic review. *Rheumatology*. 2021;60(3):1054–1066. (Oxford).
- 44 Wang L, Wang Y, Zhang P, et al. Gut microbiota changes in patients with spondyloarthritis: a systematic review. Semin Arthritis Rheum. 2021;52:151925.
- 45 Yadav SK, Boppana S, Ito N, et al. Gut dysbiosis breaks immunological tolerance toward the central nervous system during young adulthood. Proc Natl Acad Sci U S A. 2017;114(44):E9318–E9E27.
- 46 Li B, Selmi C, Tang R, Gershwin ME, Ma X. The microbiome and autoimmunity: a paradigm from the gut-liver axis. *Cell Mol Immunol.* 2018;15(6):595–609.
- 47 Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. *Nature*. 2016;535(7610):75-84.

- 48 Tajik N, Frech M, Schulz O, et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. *Nat Commun.* 2020;11(1):1995.
- 49 Nguyen Y, Mariette X, Salliot C, Gusto G, Boutron-Ruault MC, Seror R. Chronic diarrhoea and risk of rheumatoid arthritis: findings from the French E3N-EPIC cohort study. *Rheumatology*. 2020;59(12):3767–3775. (Oxford).
- 50 Kurilshikov A, Medina-Gomez C, Bacigalupe R, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. *Nat Genet*. 2021;53(2):156–165.
- 51 Wells PM, Adebayo AS, Bowyer RCE, et al. Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study. *Lancet Rheumatol.* 2020;2(7):e418–ee27.
- 52 Horvat S, Rupnik M. Interactions between clostridioides difficile and fecal microbiota in *in vitro* batch model: growth, sporulation, and microbiota changes. *Front Microbiol.* 2018;9:1633.
- 53 Frost F, Kacprowski T, Ruhlemann M, et al. Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function. *Gut.* 2021;70(3):522–530.
- 54 Zaiss MM, Joyce Wu HJ, Mauro D, Schett G, Ciccia F. The gut-joint axis in rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(4):224–237.
- 55 Camara-Lemarroy CR, Silva C, Greenfield J, Liu WQ, Metz LM, Yong VW. Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity. *Mult Scler.* 2020;26 (11):1340–1350.
- 56 Ciccia F, Guggino G, Rizzo A, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis. 2017;76(6):1123–1132.
- 57 Kim JW, Kwok SK, Choe JY, Park SH. Recent Advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus. *Int J Mol Sci.* 2019;20(19).
- 58 Brandl C, Bucci L, Schett G, Zaiss MM. Crossing the barriers: Revisiting the gut feeling in rheumatoid arthritis. Eur J Immunol. 2021;51(4):798–810.
- 59 Matei DE, Menon M, Alber DG, et al. Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease. *Med.* 2021;2(7):864–883. (N Y)e9.
- 60 Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut. 2006;55(10):1512–1520.
- 61 Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity*. 2010;32(6):815–827.
- 62 Marietta EV, Murray JA, Luckey DH, et al. Suppression of inflammatory arthritis by human gut-derived prevotella histicola in humanized mice. Arthritis Rheumatol. 2016;68(12):2878–2888.
- 63 Teng F, Klinger CN, Felix KM, et al. Gut microbiota drive autoimmune arthritis by promoting differentiation and migration of peyer's patch T follicular helper cells. *Immunity*. 2016;44(4):875– 888.
- 64 Trollmo C, Nilsson IM, Sollerman C, Tarkowski A. Expression of the mucosal lymphocyte integrin alpha E beta 7 and its ligand Ecadherin in the synovium of patients with rheumatoid arthritis. *Scand J Immunol.* 1996;44(3):293–298.
- 65 Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science*. 2013;341(6145):569–573.
 66 Asquith M, Davin S, Stauffer P, et al. Intestinal metabolites are pro-
- 66 Asquith M, Davin S, Stauffer P, et al. Intestinal metabolites are profoundly altered in the context of HLA-B27 expression and functionally modulate disease in a rat model of spondyloarthritis. *Arthritis Rheumatol.* 2017;69(10):1984–1995.
- 67 Wang W, Yang GJ, Zhang J, et al. Plasma, urine and ligament tissue metabolite profiling reveals potential biomarkers of ankylosing spondylitis using NMR-based metabolic profiles. *Arthritis Res Ther.* 2016;18(1):244.
- 68 Hager J, Bang H, Hagen M, et al. The role of dietary fiber in rheumatoid arthritis patients: a feasibility study. *Nutrients*. 2019;π(10):2392.
- 69 Lucas S, Omata Y, Hofmann J, et al. Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss. *Nat Commun.* 2018;9(1):55.
- 70 Cleophas MC, Crisan TO, Lemmers H, et al. Suppression of monosodium urate crystal-induced cytokine production by butyrate is

mediated by the inhibition of class I histone deacetylases. Ann Rheum Dis. 2016;75(3):593-600.

- 71 He J, Chu Y, Li J, et al. Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis. *Sci Adv.* 2022;8(6):eabm1511.
- 72 Qiu X, Zhang M, Yang X, Hong N, Yu C. Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohns Colitis. 2013;7(11): e558–e568.
- 73 Forbes JD, Chen CY, Knox NC, et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? *Microbiome*. 2018;6(1):221.
- 74 Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. *Inflamm Bowel Dis.* 2009;15 (8):1183–1189.
- 75 Miquel S, Martin R, Bridonneau C, et al. Ecology and metabolism of the beneficial intestinal commensal bacterium Faecalibacterium prausnitzii. Gut Microbes. 2014;5(2):146–151.
- 76 Sublette ME, Cheung S, Lieberman E, et al. Bipolar disorder and the gut microbiome: a systematic review. *Bipolar Disord.* 2021;23 (6):544-564.
- 77 Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014;111 (6):2247–2252.
- 78 McGuire T, Gerjarusak P, Hinthorn DR, Liu C. Osteomyelitis caused by beta-hemolytic streptococcus group B. JAMA. 1977;238 (19):2054–2055.
- 79 Murillo O, Roset A, Sobrino B, et al. Streptococcal vertebral osteomyelitis: multiple faces of the same disease. *Clin Microbiol Infect.* 2014;20(1):O33–O38.
- 80 Tandon R, Sharma M, Chandrashekhar Y, Kotb M, Yacoub MH, Narula J. Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol. 2013;10(3):171–177.
- 81 Cunningham MW. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol. 2014;33(4):314–329.
- 82 Barash J. Rheumatic fever and post-group a streptococcal arthritis in children. *Curr Infect Dis Rep.* 2013;15(3):263–268.
- Mackie SL, Keat A. Poststreptococcal reactive arthritis: what is it and how do we know? *Rheumatology*. 2004;43(8):949–954. (Oxford).
 Boer CG, Radjabzadeh D, Medina-Gomez C, et al. Intestinal micro-
- 84 Boer CG, Radjabzadeh D, Medina-Gomez C, et al. Intestinal microbiome composition and its relation to joint pain and inflammation. *Nat Commun.* 2019;10(1):4881.
- 85 Walter J. Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research. *Appl Envi*ron Microbiol. 2008;74(16):4985–4996.
- 86 Liu F, Ren T, Li X, et al. Distinct microbiomes of gut and saliva in patients with systemic lupus erythematous and clinical associations. Front Immunol. 2021;12: 626217.
- 87 Tito RY, Cypers H, Joossens M, et al. Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. *Arthritis Rheumatol.* 2017;69(1):114-121.
- 88 Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. *Elife.* 2013;2:e01202.
- 89 Mizuno M, Noto D, Kaga N, Chiba A, Miyake S. The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models. *PLoS One*. 2017;12:(2) e0173032.
- 90 Dessein PH, Solomon A, Hollan I. Metabolic abnormalities in patients with inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2016;30(5):901–915.
- 91 Bengtsson AA, Trygg J, Wuttge DM, et al. Metabolic profiling of systemic lupus erythematosus and comparison with primary sjogren's syndrome and systemic sclerosis. PLoS One. 2016;11:(7) e0159384.
- 92 Heintz-Buschart A, Wilmes P. Human gut microbiome: function matters. *Trends Microbiol.* 2018;26(7):563–574.
- 93 de Paiva CS, Jones DB, Stern ME, et al. Altered mucosal microbiome diversity and disease severity in sjogren syndrome. Sci Rep. 2016;6:23561.